The novel myosin ATPase inhibitor improved exercise capacity and symptoms in a placebo-controlled, randomized trial.
In patients with obstructive hypertrophic cardiomyopathy (oHCM), alleviating symptoms of dynamic left-ventricular outflow tract (LVOT) obstruction can be challenging. Available medical therapies — beta-blockers, nondihydropyridine calcium-channel blockers (CCBs), or disopyramide — might not suffice, prompting consideration of invasive septal-reduction procedures. In PIONEER-HF, a small, manufacturer-funded, open-label phase 2 trial, the selective myosin ATPase inhibitor mavacamten markedly reduced postexercise LVOT gradients in patients with oHCM. The drug maker has now funded a multinational phase 3 trial, EXPLORER-HCM (NCT03470545), to assess mavacamten's effect on exercise capacity and symptoms in this population.
The 251 participants (me…
Reviewing Author
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)